Why BGPT?
logo

Graphs Built From Reported Results

Turn exact figures reported in papers into graphs, each point traced to its source.Know what the science actually supports before you trust the answer.

Press Enter ↵ to create graph


     Long Analysis Plan



    The requested graph cannot be built from the supplied evidence. None of the eight claim-level records contain bleeding, coagulation, platelet, or adverse-event safety data for EGb 761 — they cover amyloid pathology (C. elegans PT50, deposit counts ), cholesterol flux, rat pharmacokinetics, glaucoma, neuropathic pain, and dementia pharmacoeconomics.

    The only bleeding-adjacent item is trial registration NCT00689858 (Phase 1, cilostazol + Ginkgo biloba PK/PD interaction in healthy volunteers, completed), but no results data were supplied. The "bleeding risk theory vs clinical signals" comparison therefore lacks both theory-side and clinical-side quantitative inputs here. Needed to proceed: pooled adverse-event rates (bleeding events per arm) from EGb 761 RCTs, anticoagulant/antiplatelet co-administration data, and platelet-function assay results.



    Feedback:    

    Updated: September 13, 2026



     Top Data Sources ExportMCP



     Hypothesis Graveyard



    Hypothesis that the bleeding signal is established clinically from supplied data: falsified by absence — no record reports bleeding outcomes, so neither confirming nor refuting data exist here.

     Science Art


    Create Graphs: Ginkgo EGb 761 safety signals (bleeding risk theory vs clinical signals) Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT